TABLE 3.

Plasma Aβ42, Aβ40, Aβ42/Aβ40, t-tau, and 18F-florbetapir PET SUVR for NC, SCD, MCI, and AD in individuals with Aβ-PET (+).

Plasma biomarkers	NC (n = 38)	SCD (n = 27)	MCI (n = 43)	AD (n = 56)	F (P-value)
Aβ42 (pg/ml)	9.52 ± 1.89	10.83 ± 3.10	9.45 ± 2.58	7.80 ± 2.52	6.59 (<0.001)
Aβ40 (pg/ml)	186.47 ± 26.93	211.46 ± 47.05	194.72 ± 43.10	186.41 ± 49.21	1.78 (0.152)
Aβ42/Aβ40 (ratio)	0.0517 ± 0.0110	0.0519 ± 0.0136	0.0493 ± 0.0116	0.0428 ± 0.0129	3.01 (0.032)
T-tau (pg/ml)	2.05 ± 0.84	2.39 ± 0.89	2.41 ± 0.99	2.54 ± 1.23	2.46 (0.064)
18F-florbetapir PET SUVR	1.23 ± 0.10	1.28 ± 0.13	1.35 ± 0.22	1.41 ± 0.22	11.93 (<0.001)

NC, cognitively normal controls; SCD, subjective cognitive decline; MCI, mild cognitive impairment; AD, Alzheimer’s disease; 18F-florbetapir PET, 18F-florbetapir positron emission tomography; SUVR, standard uptake value ratios. P-values were adjusted for age, sex, and education years with general linear models. The bold values represented the values with statistical significance.